|1.||Hayakawa, Yoshihiro: 14 articles (10/2015 - 03/2005)|
|2.||Hyodo, Mamoru: 12 articles (10/2015 - 03/2005)|
|3.||Karaolis, David K R: 7 articles (09/2014 - 03/2005)|
|4.||Waters, Christopher M: 5 articles (11/2014 - 01/2011)|
|5.||Liu, Zhi-Jie: 4 articles (03/2014 - 06/2012)|
|6.||Ouyang, Songying: 4 articles (03/2014 - 06/2012)|
|7.||Chou, Shan-Ho: 3 articles (10/2015 - 08/2012)|
|8.||Chin, Ko-Hsin: 3 articles (10/2015 - 08/2012)|
|9.||Givskov, Michael: 3 articles (07/2015 - 08/2012)|
|10.||Tolker-Nielsen, Tim: 3 articles (07/2015 - 08/2012)|
09/01/2011 - "Our results showed that 50 μg of c-di-GMP administered 18 h prior to infection provided the best protection against intranasal infection with A. "
07/30/2009 - "Our results show that c-di-GMP should be developed as an adjuvant and immunotherapeutic to provide protection against systemic infection caused by S. "
07/30/2009 - "c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection."
01/01/2015 - "aeruginosa with elevated levels of c-di-GMP during the initial infection produces an increased bacterial burden in the bladder and kidneys. "
01/01/2015 - "During infection, the innate immune system can also sense c-di-GMP; however, whether bacterial pathogens utilize c-di-GMP as a weapon to fight against host defense for survival and possible mechanisms underlying this process remain poorly understood. "
|2.||Bacterial Infections (Bacterial Infection)
09/25/2009 - "These results, for the first time, provide direct evidence for the induction of protection against mucosal bacterial infections by cdiGMP as an adjuvant."
08/01/2013 - "In Gram-negative bacteria, production of the signal molecule c-di-GMP by diguanylate cyclases (DGCs) is a key trigger for biofilm formation, which, in turn, is often required for the development of chronic bacterial infections. "
08/26/2008 - "Cyclic diguanylate (c-di-GMP) is a unique bacterial intracellular signaling molecule capable of stimulating enhanced protective innate immunity against various bacterial infections. "
07/01/2012 - "The structural biology of c-di-GMP receptors is a rapidly developing field of research, which holds promise for the development of novel therapeutics against bacterial infections. "
04/07/2015 - "Our results define machinery underlying the dynamic regulation of HSPCs and their niches during bacterial infection through c-di-GMP/STING signaling. "
|3.||Bites and Stings (Sting)
08/01/2012 - "Crystallization studies of the murine c-di-GMP sensor protein STING."
06/29/2012 - "This study provides a glimpse into the unique architecture of STING and sheds light on the mechanism of c-di-GMP-mediated TBK1 signaling."
04/07/2015 - "Here, we report that c-di-GMP comprehensively regulated both HSPCs and their niche cells through an innate immune sensor, STING, thereby inducing entry into the cell cycle and mobilization of HSPCs while decreasing the number and repopulation capacity of long-term hematopoietic stem cells. "
04/07/2015 - "Bacterial c-di-GMP affects hematopoietic stem/progenitors and their niches through STING."
06/01/2014 - "3'3'-cG(d2AP)MP can also form a heterodimer with cGAMP, activator of immune regulator, STING, or the bacterial biofilm regulator, c-di-GMP in the presence of Mn(II). "
09/01/2014 - "Experiments revealed that c-di-GMP targets myeloid-derived suppressor cells (MDSC) and tumor cells. "
04/01/2006 - "Besides its role as an intracellular signaling molecule in bacteria, c-di-GMP also acts as an intercellular signaling molecule between prokaryotes and also has effects in eukaryotes that could provide a perspective in cancer treatment."
04/01/2005 - "In the present communication, we report that c-di-GMP (50 microM) has striking properties regarding inhibition of cancer cell proliferation in vitro. "
09/01/2014 - "This finding correlated with a mechanism of improved CD8 T-cell responses to tumor-associated antigens (TAA) Mage-b and Survivin, most likely through cross-presentation of these TAAs from c-di-GMP-killed 4T1 tumor cells, and through c-di-GMP-activated TAA-specific T cells. "
04/01/2005 - "Cyclic dinucleotides, such as c-di-GMP, represent an attractive and novel "drug-platform technology" that can be used not only to develop new antimicrobial agents, but also to develop novel therapeutic agents to prevent or treat cancer."
|5.||Respiratory Tract Infections (Respiratory Tract Infection)
|2.||Caspase 3 (Caspase-3)
|3.||Interleukin-12 (IL 12)
|5.||5'-Guanylic Acid (GMP)
|6.||Adenosine Monophosphate (AMP)
|9.||Interleukin-6 (Interleukin 6)
|10.||bis(3',5')-cyclic diguanylic acid